Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant as Adjunctive Treatment in Schizophrenia
NCT07615426Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aticaprant in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoints: Screen Pass Rate up to 28 days, Exploratory Assessment-Specific Completion Rate up to 126 days and 10 more. Started Mar 2026; status: recruiting.
02
Drugs
aticaprant
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07615426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615426.